Navigation Links
Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
Date:8/25/2010

Pharmaceutical manufacturers are the most common APAC M&A targets 74

Leading pharma players have preferences for specific sectors 78

Acquirers target highest value and volume therapeutic areas 79

4. Country specific M&A activity 81

Key findings 81

*Australia had a strong start to 2010 82

M&A summary 84

China showed mainly domestic M&A activity, although international deals are on the rise 85

M&A summary 87

M&A activity in India was particularly high in 2008, then dropped off again 88

M&A summary 90

Japan saw biggest deal of the region when it purchased Indian generics company in 2008 91

M&A summary 93

Most Malaysian M&A deals involved the broader healthcare industry 94

M&A summary 95

M&A activity in New Zealand slowed down considerably in 2009-10 96

M&A summary 97

Singaporean companies were particularly active as acquirers 98

M&A summary 99

M&A activity in South Korea is increasing consistently 100

M&A summary 101

The majority of M&A deals in Taiwan took place in 2008 102

M&A summary 103

Other APAC countries were involved in few M&A deals from Q1 2007-Q1 2010 104

Indonesia 104

Philippines 104

Thailand 105

Vietnam 105

Significant M&A in APAC has continued throughout the first half of 2010 106

Abbott acquires formulations business of India's leading pharmaceutical firm 106

Indian pharmaceutical industry grows wary of multinational dominance 106

GlaxoSmithKline focuses on small acquisitions in emerging markets 107

GlaxoSmithKline invests in South Korea 108

GlaxoSmithKline cannot find value in Indian acquisitions 108

Chinese CRO deal falters 108

International players continue to expand presence in APAC through means other than M&A 109

5
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
2. Reportlinker Adds Production and Market of Xylose in China
3. Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED
4. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
5. Reportlinker Adds Japanese Market for Small Joint Reconstructive Devices 2010
6. Reportlinker Adds Effective Social Media Marketing Strategies for Pharmaceutical Market
7. Reportlinker Adds Wireless Medical Technologies 2007-2010
8. Reportlinker Adds European Market for Ventilation and Airway Management Devices
9. Reportlinker Adds Western European Disinfectant Gels and Scrubs Market
10. Reportlinker Adds Global Pharma-biotech Alliance Analysis
11. Reportlinker Adds 2010 U.S. Ophthalmologists Assessment of Eye Care Medication Brands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium ... today positive preliminary results from its Phase II ... prednisone (D/P) in men with docetaxel refractory, castrate ... of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in ...
... Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation ... the status of its new drug application ("NDA") for AFRESA(R), ... trials. As previously announced, our internal goal was to ... by the end of February. Based on editorial decisions ...
Cached Medicine Technology:Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 2Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 3Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 4MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
(Date:10/22/2014)... By Dennis Thompson HealthDay ... freelance cameraman who was diagnosed with Ebola while working for ... system and can leave the special isolation unit at Nebraska Medical ... two weeks, the hospital said Tuesday. A blood test confirmed ... Ashoka Mukpo, 33, can head home to Providence, R.I., NBC ...
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 ... joined Specialists in Obstetrics & Gynecology of Columbus, Inc., ... specialized women’s healthcare services to more than 100,000 patients ... care though all ages and stages of a women’s ... office locations in Westerville and Dublin. , ...
Breaking Medicine News(10 mins):Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... Reporter , MONDAY, Sept. 13 (HealthDay News) -- The U.S. ... this week whether or not the diet drug Meridia should ... released Monday ahead of the panel meeting, which begins Wednesday, ... Drugs Advisory Committee will be asked to consider a number ...
... of the National Institutes of Health, announced today that ... Institutes in San Francisco, Calif., has been selected as ... HIV/AIDS Research for his proposal to study the mechanisms ... now in its third year, is intended to stimulate ...
... study describing a newly developed pharmacological inhibitor is providing ... implicated in multiple human malignancies regulates a known tumor ... September 14th issue of the journal Cancer Cell ... Mitogen-activated protein kinases (MAPKs) are enzymes that regulate ...
... that spurs the progression of non-small-cell lung cancer could become ... Southwestern Medical Center, who published a study on how the ... Cancer Cell . Scientists have known that the ... human tumors, including non-small-cell lung cancer (NSCLC). Until now, however, ...
... Earthy or musty odors, along with visual evidence of ... a warning that harmful cyanotoxins are present in lakes ... cyanobacterial blooms in Midwest lakes, taste-and-odor compounds were found ... serve as a warning that harmful toxins are present. ...
... findings from a major drug trial have brought experts a ... of British deaths from heart attacks. Dr Robert ... at Sheffield Teaching Hospitals, was the UK lead for international ... place over the last six years. The new findings ...
Cached Medicine News:Health News:FDA Panel to Mull Ban on Diet Drug Meridia 2Health News:FDA Panel to Mull Ban on Diet Drug Meridia 3Health News:Latent HIV infection focus of NIDA's 2010 Avant-Garde Award 2Health News:Selective inhibition of BMK1 suppresses tumor growth 2Health News:Lung cancer culprit could offer target for therapy, UT Southwestern researchers report 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Breakthrough in drug trial offers hope for heart attack patients 2
... facilities, recreational venues and more ... provide automated data capture that ... reducing costly and dangerous errors. ... print quality and color-coding options ...
... Laser Sheeted Wristband / ... laser-printable sheets with an ... laser labels that adhere ... clear, fold-over protective window ...
As part of a complete all-in-one system, Sentry LabelBand securely seals inexpensive paper labels inside a clear, adhesive shield. LabelBand provides easy and accurate bar code scanning and protectio...
... Thermal Printing Wristbands and Tags print ... and thermal transfer printers. Direct thermal ... heat-sensitive thermal coating under the bands ... heat to transfer highly durable ink ...
Medicine Products: